Please assess the completion status of the following clinical trial:

Trial Title: Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients primarily referred for disabling, unexpected fatigue.~* According to the Fukuda criteria, diagnostic work-up yields a final diagnosis of chronic fatigue (CF) or chronic fatigue syndrome (CFS).~* 18 \<= age \<= 65~* Polysomnography Test (PSG) demonstrates an apnea-hypopnea index (AHI) \>=15, as evidence for obstructive sleep apnea (OSA).~* Female patient of childbearing potential (premenopausal female biologically capable of becoming pregnant) has a confirmed negative pregnancy test at the start of the Continuous Positive Airway Pressure (CPAP) trial and has to employ an acceptable method of birth control.~* Written, signed and dated informed consent must be obtained from each patient.~* Patient able to understand and follow the requirements of the study and to comply.~* Willing to abstain from taking any medication or treatment prohibited in the protocol.~Exclusion Criteria:~* Patients primarily referred for Excessive Daytime Sleepiness (EDS) or snoring.~* Fatigue that is explained by medical or psychiatric causes.~* 18 \> age \> 65~* Apnea-Hypopnea Index (AHI) \< 15~* Body Mass Index (BMI) \>= 40, calculated as weight(m)/(height (m))²~* Parasomnia~* Severe sleepiness with (Epworth Sleepiness Scale) ESS \>= 16 (=15% of the Chronic fatigue syndrome (CFS) population)~* Tonsillar hypertrophy (Friedman grade III and IV tonsils)~* Signs of nasal obstruction, including chronic use of topical nasal drugs.~* Earlier CPAP treatment~* Physical and mental disability that compromises the normal use of CPAP~* CPAP intolerance~* Current use of sedative (benzodiazepine and non-benzodiazepine GABA-esgic agonist) or antidepressant medication for a time period inferior to 3 weeks.~* Female patient who is pregnant, lactating or has a positive pregnancy test result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active/Sham CPAP (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).